# Junta clínica — PT-pseudo_47d8b39fd07f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47d8b39fd07f",
  "pid": "PT-pseudo_47d8b39fd07f",
  "task": 1,
  "psa": 21.0,
  "age": 60,
  "months": 1,
  "pirads": "3",
  "psad": 0.19,
  "psav": 5.99,
  "psap": 23.5,
  "vol": 112.15,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.4009605,
  "medhx": "Hypertension, COPD",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.",
  "pmhx": [
    "Hypertension",
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "186 cm",
    "bmi": "22.5",
    "bp": "140/82 mmHg",
    "hr": "74 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy."
    },
    {
      "s": "History",
      "t": "The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired baker",
  "marital": "Married",
  "living": "Lives with adult child (multi-generational household)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Physiotherapy — lower back, six sessions",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "7 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.31
  uncertainty  +/- 0.16 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.89 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Negative (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 60 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 21 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 112.15 mL (1% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.40 (1% of my signal; from cspca) · PI-RADS = 3 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 3
  important  prior biopsy = Negative
  noted      age = 60 · DRE = Normal · PSA = 21 ng/mL · prostate volume = 112.15 mL · PSA density = 0.19 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: borderline — the rule matched the reading urologist in 16 of 18 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 17 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.67: PI-RADS 3, PSA 7.4, PSAD 0.16, age 61, DRE Normal -> DEFER (uncertain). He wrote: "At what PSA level the prior biopsy was taken? If PIRADS 3 is new and PSA is significantly rising since last biopsy I would consider repeat biopsy an option"
  2. distance 2.54: PI-RADS 4, PSA 9.2, PSAD 0.16, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Again earlier MRI report is missing, If new PRADS 4 lesion biopsy is needed as PSA is rising as well"
  3. distance 2.55: PI-RADS 4, PSA 8.8, PSAD 0.09, age 52, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 52 Y old patient."

PRECEDENT: BIOPSY (weighted vote 0.57 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  age = 60 · PSA = 21 ng/mL · PSA density = 0.19 · PI-RADS = 3
  noted      prior biopsy = Negative · DRE = Normal · prostate volume = 112.15 mL · csPCa probability = 0.40 · comorbidity = 2 on the problem list
  not used   family history
CONFIDENCE: borderline — the library is right 78% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 17 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Negative
  important  age = 60 · PSA = 21 ng/mL · PI-RADS = 3
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 112.15 mL · PSA density = 0.19 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. The guideline states: "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline treats the PI-RADS score as a trigger for biopsy, whereas EXPERT-COHORT marks PI-RADS 3 as decisive, suggesting the guideline makes the PI-RADS score context rather than a direct trigger. The guideline requires the prior grade, a comparison MRI, or a due confirmatory biopsy to be established to guide the decision.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the note states the chief complaint is rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy; if the prior biopsy was negative, the guideline suggests considering follow-up or direct repeat biopsy dependant of risk factors.
radiology_report - the report provides the PI-RADS score of 3, which the guideline makes decisive; if the PI-RADS score is 3, the guideline suggests biopsy is triggered.
psa_trend - the trend shows a rising PSA trajectory, which the guideline makes decisive; if the PSA trend is rising, the guideline suggests considering follow-up or direct repeat biopsy dependant of risk factors.
laboratory_results - the laboratory results show the PSA value of 21.0 ng/mL, which the guideline makes decisive; if the PSA value is 21.0 ng/mL, the guideline suggests considering follow-up or direct repeat biopsy dependant of risk factors.
family-history anamnesis - the family history anamnesis is not opened, which the guideline makes decisive; if the family history anamnesis is not opened, the guideline suggests considering follow-up or direct repeat biopsy dependant of risk factors.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on whether the rising PSA trend and PI-RADS 3 warrant a repeat biopsy given the negative prior result, and we need to establish the context from the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, and is there an extraprostatic extension noted?
  psa_trend (get_psa_trend) -> What is the specific pattern of the serial PSA values (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the GRADE of the prior biopsy, and is there an established surveillance protocol?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE of the prior biopsy as documented in the previous notes?
  Q2. Does the rising PSA trajectory warrant a repeat biopsy given the PI-RADS 3 finding?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: mpMRI Prostate | LUMC | 15 Jan 2025
Lesion: 12 mm focus in the right mid-gland peripheral zone. Extracapsular extension is absent.
psa_trend
The specific pattern of the serial PSA values is rising, from 2.5 (Mar 2022) to 21.0 (Jan 2025).
previous_notes
PRIOR GRADE: Negative
SURVEILLANCE: not recorded
TREATMENT: none recorded

WHAT I DID NOT OPEN
family-history anamnesis, because it could not have changed the answer.

WHAT THIS SUPPORTS
FOR sampling this patient now
The rising PSA trajectory (2.5 to 21.0 ng/mL) supports further investigation.
The PI-RADS 3 finding, combined with a rising PSA, aligns with the EAU guideline trigger.
AGAINST sampling this patient now
The prior biopsy was Negative, which argues against immediate repeat biopsy based on the cohort criterion.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 21.00 ng/mL over 4 points spanning 34 months; velocity +7.18 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 21 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.44
  uncertainty  +/- 0.15 epistemic (95% band 0.15-0.74), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Negative (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 3 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 21 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 112.15 mL (4% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.31  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.44  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.57  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_3) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Negative                     E1:DEC E3:DEC cohort:IMP library:not E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          60                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          21 ng/mL                     E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          112.15 mL                    E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.19                         E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.40                         E1:not E3:— cohort:— library:not E2:—                -> not_used
  pirads       3                            E1:not E3:IMP cohort:DEC library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) answered the moderator's questions to some extent. The registrar reported the prior biopsy grade as "Negative" and the PSA trend as "rising, from 2.5 (Mar 2022) to 21.0 (Jan 2025)".

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PI-RADS $\le 3$) fired, which is the rule that carried the decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE of the prior biopsy as documented in the previous notes? Answered by the registrar: PRIOR GRADE: Negative.
Q2. Does the rising PSA trajectory warrant a repeat biopsy given the PI-RADS 3 finding? This is not explicitly answered by a single document, but the registrar noted the rising trend, which supports the EAU guideline trigger, while the cohort criterion argues against it.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 21 ng/mL (noted) because the rising PSA trajectory (2.5 to 21.0 ng/mL) supports further investigation, aligning with the EAU guideline trigger.
prior biopsy: decisive: Negative because the cohort criterion (PI-RADS $\le 3$) was decisive, and the negative prior biopsy argues against immediate repeat biopsy based on that rule.
pirads: important: 3 (important) because the cohort criterion (pirads\_le\_3) was decisive, leading to the panel's decision.
MY SUGGESTION TO THE CHAIR
I suggest deferral, as the PANEL-PROTOCOL's answer rests on the cohort criterion, which was triggered by the PI-RADS 3 finding, despite the rising PSA trajectory.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

60y/o, PSA 21.0, PSAD 0.19, PI-RADS 3, prior negative biopsy. PI-RADS 3 without rising PSAD does not justify repeat biopsy. Re-imaging in one year is an alternative plan if lesion changes.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
